Mr Vincent Gnanapragasam

University of Cambridge

University departments
Department of Oncology
NHS or other affiliations
Departments of Urology and Surgery

Position: University Lecturer in Uro-oncology and Consultant Urologist
Personal home page:

PubMed journal articles - click here

Mr Vincent Gnanapragasam is pleased to consider applications from prospective PhD students.

Research description

Vincent Gnanapragasam graduated with BMedSci and MBBS degrees from Newcastle University. Following basic surgical training, he was one of the first trainees to be funded through a Cancer Research UK PhD for Clinicians. Whilst undertaking Higher Specialist Training in Urology in the North East, Vincent was appointed as Urology First Assistant (Clinical Lecturer) at Newcastle University in 2003.

In 2004, supported by the first CRUK Clinician Scientist Fellowship given to a surgeon, Vincent established his own research laboratory group. This work revealed novel insights into the role of negative signalling regulators in cancer metastasis and progression. He moved to Cambridge following the award of a HEFCE Senior Lectureship in 2007.

He is currently a University Lecturer at the University of Cambridge, and Honorary Consultant Urologist at Addenbrooke’s Hospital, Cambridge. Vincent’s research covers the full spectrum of basic science, translational, clinical and epidemiological disciplines in prostate cancer. He is CI of 3 multi-centre trials: the NIHR i4i funded CAMPROBE study, Predict Prostate RCT and PRIM bio-marker/imaging study. As well as this, he leads investigator initiated translational studies including the TAPS01 (Janssen) and ICON (CRUK) studies.

He is also Chief Investigator of the Cambridge Urological Biorepository which holds a unique collection of >6000 samples, biofluids and data on urological cancers and benign disease currently being used in over 50 research studies in Cambridge and internationally. He has developed the concept of precision medicine in primary aggressive prostate cancer through pilot work in a virtual molecular MDT. He is a member of the UK ICGC prostate group and on the clinical working group of the International Pan Prostate Cancer Collaborative and GAP 3 Active Surveillance consortium. He has developed novel more accurate prognostic prediction models for both group stratified cohorts Cambridge Prognostics Groups and for individualised prediction Prostate Predict and pioneered risk stratified pathways for active surveillance follow up.

To date he has raised over £9M in research grant funding and published over 120 peer reviewed papers, many in very high impact papers e.g. Nature, Nature Genetics, Plos Med, BMC Med and European Urology. His work has been cited many times and endorsed in national prostate cancer guidelines by NICE and the European Association of Urology. Prognostic tools he has developed are now recommended for use by CRUK and MacMillan Cancer Support amongst others, and have entered routine clinical practice.

In the University of Cambridge, he (i) leads the University Academic Urology Group in the Department of Surgery, (ii) Co-leads the CRUK Cambridge Cancer Centre Urological Malignancies Programme and (iii) Established and directs the Cambridge Urology Translational Research and Clinical Trials (CUTRACT) office. He holds patents and has won numerous prizes for research including the CE Alken prize, Urological Research Society Medical and a Hunterian Professorship. His students have been awarded many prizes including the EAU residents prize and Urology Foundation medal. He has had many national leadership roles is a Visiting Professor at Anglia Ruskin University having established a Urology Masters programme there for junior urology clinical trainees.

Research Programme
Urological Malignancies
Methods and technologies
Cell culture
Clinical practice
Clinical trials
Gene expression profiling
Magnetic Resonance Imaging (MRI)
Public health
Tumour type interests
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Thurtle DR, Jenkins VL, Pharoah PD, Gnanapragasam VJ. Understanding of prognosis in non-metastatic prostate cancer: A randomised comparative study 2 of clinician estimates measured against the PREDICT prostate prognostic model. Br J Cancer (2019) IF 5.9 (In Press)

Thurtle DR, Greenberg DC, Lee LS, Huang HH, Pharoah PD, Gnanapragasam VJ. Individual prognosis at diagnosis in non-metastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model. PLoS Med (2019) IF 11.7 Mar 12;16(3):e1002758. doi: 10.1371/journal.pmed.1002758.

Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, Rubio-Briones J, Domínguez-Escrig J, Bratt O, Statin P, Muir K, Lophatananon A. Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer. BJU Int. (2019) IF 4.5 May 7. doi:10.1111/bju.14800.

Thurtle D, Starling L, Leonard K, Stone T, Gnanapragasam VJ. Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method. J Clin Urol. (2018) IF pending May;11(3):192-199.

Wedge DC et al.Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. (2018) May;50(5):682-692. doi: 10.1038/s41588-018-0086-z. IF 29.6 Mar 2. doi: 10.1038/ng.3221. ICGC Prostate Group.

Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med (2018) IF 9 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5. PubMed PMID: 29490658

Thurtle D, Barrett T, Thankappan-Nair V, Koo B, Warren A, Kastner C, Saeb-Parsy K, Kimberley-Duffell J, Gnanapragasam VJ. Progression and treatment rates using an active surveillance protocol incorporating image-guided baseline biopsies and multiparametric magnetic resonance imaging monitoring for men with favourable-risk prostate cancer. BJU Int. (2018) Feb 13. doi: 10.1111/bju.14166.

Hori S, Wadhwa K, Pisupati V, Zecchini V, Ramos-Montoya A, Warren AY, Neal DE, Gnanapragasam VJ. Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. Int J Cancer (2017) IF 7.3 Jan 10. doi: 10.1002/ijc.30604..

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study. PLoS Medicine (2016) IF 14.4

Gnanapragasam VJ, Burling K, George A, Stearn S, Warren A, Barrett T, Koo B, Gallagher FA, Doble A, Kastner C, Parker RA. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population. Sci Rep (2016) IF 5.2 Oct 17;6:35364. doi:10.1038/srep35364.

The evolutionary history of lethal metastatic prostate cancer. Gundem et al. ICGC Prostate Group, Nature (2015) Apr 16;520(7547):353-7.

Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. DA Greenberg, A Lophtananon, K Wright,K Muir and VJ Gnanapragasam Plos One (2015)Mar 5;10(3):e0119494.

Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. M Hong et al  Nature Communications (2015)

Active Surveillance of prostate cancer: A questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the UK Y Philippou, VJ Gnanapragasam BMC Urology (2015)

Comparative oncological and toxicity outcomes of salvage radical prostatectomy versus non-surgical therapies for radio-recurrent prostate cancer: A meta-regression analysis. Y Philippou,  RA Parker, D Volanisc, VJ Gnanapragasam European Urology Focus (2015)

Integration of copy number and transcriptomics improves risk stratification in prostate cancer. H Ross-Adams et al E Bio Medicine (2015)

The ADC ratio of tumor to normal prostate as a method for quantifying diffusion weighted imaging of the prostate. T Barrett, AN Priest, EM Lawrence, DA Goldman, AY Warren, VJ Gnanapragasam, E Sala,, A Gallagher Am J Roentgenol (2015)

Primary radical therapy selection in high-risk non-metastatic prostate cancer. VJ Gnanapragasam, I Syndikus, H Kynaston and T Johnstone Clinical Oncology (2015)

Incidence of needle tract seeding after prostate biopsy for suspected cancer. D Volanis, DE Neal, VJ Gnanapragasam BJU International (2015)

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Cooper CS et al. ICGC Prostate Group, Nat Genet. (2015) Mar 2. doi: 10.1038/ng.3221. [Epub ahead of print]

Multi-transcript profiling in diagnostic archival needle biopsies to investigate predictive biomarker in non-surgical therapy for prostate cancer.N Kachroo, AY Warren and VJ Gnanapragasam BMC Cancer (2014) Sep 16;14:673.

Molecular markers to guide primary radical treatment selection in localised prostate cancer. VJ Gnanapragasam. Expert Reviews in Molecular Diagnostics (2014) Sep;14(7):871-81

Evolution of repeat prostate biopsy strategies incorporating transperineal and MRI-TRUS fusion techniques. Kuru TH, Saeb-Parsy K, Cantiani A, Frey J, Lombardo R, Serrao E, Gaziev G, Koo B, Roethke M, Gnanapragasam V, Warren A, Doble A, Hadaschik B, Kastner C. World J Urol (2014) Aug;32(4):945-50

Prostate cancer performance characteristics of combined T(2)W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion.Lawrence EM, Tang SY,  Barrett T, Koo B, Goldman DA, Warren AY, Axell RG, Doble A, Gallagher FA, Gnanapragasam VJ, Kastner C, Sala E. Eur Radiol. (2014) Jul;24(7):1497-505

Pre-operative 3-tesla diffusion weighted MRI for the qualitative and quantitative assessment of  extracapsular extension in patients with intermediate or high-risk prostate cancer. EM. Lawrence, FA Gallagher, T Barrett, A Warren, AN Priest, E Sala, VJ Gnanapragasam. Am J Roentology (2014) Sep;203(3):W280-6

Changing presentation of prostate cancer in a UK population: 10 year trends in risk profiles in the East of England. DA Greenberg, K Wright, A Lophatanon, K Muir, VJ Gnanapragasam. British Journal of Cancer (2013) Oct 15;109(8):2115-20

Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy.­­ AW Nelson, RC Harvey, RA Parker, C Kastner, A Doble, VJ Gnanapragasam PLOS One(2013) 8(2):e57480. doi: 10.1371/journal.pone.0057480

The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer-a systematic review. N Kachroo, VJ Gnanapragasam Journal of Cancer Research and Clinical Oncology (2013) Jan;139(1):1-24.

Evidence for down-regulation of the negative regulator SPRED2 in clinical prostate cancer. N Kachroo, T Valencia, A Warren, VJ Gnanapragasam. British Journal of Cancer (2013) Feb 19;108(3):597-601.

Risk profiles of prostate cancers identified from UK primary care using national guidelines. H Serag, S Banerjee, K S Parsy, S Irving, K White, S Stearn, A Doble, VJ Gnanapragasam. British Journal of Cancer (2012) Jan 31;106(3):436-9